A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes

NANot yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

July 30, 2027

Conditions

Type 2 Diabetes

Interventions

DRUG

Cofrogliptin

10mg administered once every two weeks

DRUG

Acarbose

50mg administered 3 times daily

Trial Locations (1)

He'nan Provincial People's Hospital, Zhengzhou

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY